N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

A method of reducing cannabinoid blood absorption inter-subject variability, the method comprising:

• administering to a plurality of subjects an oral formulation comprising a cannabinoid with an aqueous solubility of less than 0.1 mg/ml selected from:
• Δ9-Tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinol propyl variant (CBNV), cannabitriol (CBO), and/or mixtures thereof;
• and an N-acylated fatty amino acid or salt thereof having a formula:
• wherein X is sodium or potassium, and Z is hydrogen,
• wherein the weight/weight (w/w) ratio of cannabinoid/N-acylated fatty amino acid or salt thereof within the oral formulation is 1:6 or 1:10;
• thereby reducing the cannabinoid blood absorption inter-subject variability,
• wherein the reduced cannabinoid blood absorption inter-subject variability is evidenced by a coefficient of variation (% CV) of area under a plasma concentration-time curve that is less than 50%.